Literature DB >> 26270825

Irrational Exuberance in Testosterone Prescribing: When Will the Bubble Burst?

David J Handelsman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26270825     DOI： 10.1097/MLR.0000000000000416

Source DB:  PubMed          Journal:  Med Care        ISSN： 0025-7079            Impact factor:   2.983


× No keyword cloud information.
  4 in total

1.  Who Gets Testosterone? Patient Characteristics Associated with Testosterone Prescribing in the Veteran Affairs System: a Cross-Sectional Study.

Authors:  Guneet K Jasuja; Shalender Bhasin; Joel I Reisman; Joseph T Hanlon; Donald R Miller; Anthony P Morreale; Leonard M Pogach; Francesca E Cunningham; Angela Park; Dan R Berlowitz; Adam J Rose
Journal:  J Gen Intern Med       Date:  2016-12-19       Impact factor: 5.128

2.  Testosterone replacement therapy is associated with an increased risk of urolithiasis.

Authors:  Tyler R McClintock; Marie-Therese I Valovska; Nicollette K Kwon; Alexander P Cole; Wei Jiang; Martin N Kathrins; Naeem Bhojani; George E Haleblian; Tracey Koehlmoos; Adil H Haider; Shehzad Basaria; Quoc-Dien Trinh
Journal:  World J Urol       Date:  2019-03-23       Impact factor: 4.226

3.  Testosterone treatment and risk of venous thromboembolism: population based case-control study.

Authors:  Carlos Martinez; Samy Suissa; Stephan Rietbrock; Anja Katholing; Ben Freedman; Alexander T Cohen; David J Handelsman
Journal:  BMJ       Date:  2016-11-30

Review 4.  Testosterone therapy in the new era of Food and Drug Administration oversight.

Authors:  Bethany Desroches; Taylor P Kohn; Charles Welliver; Alexander W Pastuszak
Journal:  Transl Androl Urol       Date:  2016-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.